Lung alert

Neoadjuvant chemotherapy in operable non-small cell lung cancer

Survival for patients with non-small cell lung cancer (NSCLC) has remained unchanged for over 10 years. This randomised controlled trial assessed the benefits of neoadjuvant chemotherapy in patients with operable NSCLC.

519 patients were randomised to receive surgery as soon as possible or chemotherapy as soon as possible followed by surgery 4–6 weeks from day 1 of the last chemotherapy cycle. Patients with stage I–III disease were included. The primary outcome measure was overall survival, and secondary outcome measures included quality of life, clinical and pathological staging, resectability rates, extent of surgery, and the time to and site of relapse.

There was no difference in overall survival between the two treatment groups. 31% of patients receiving chemotherapy before surgery were down-staged at the time of surgery; however, this did not alter the type of surgery they had. A very small proportion of patients progressed during chemotherapy. Surgery did not appear to be affected by the time taken to deliver neoadjuvant chemotherapy. With regard to baseline symptoms and quality of life, neoadjuvant chemotherapy had a minimal effect. Patterns of recurrence and progression were also not affected by chemotherapy except for the fact that more of the patients who underwent chemotherapy before surgery developed brain metastases.

This trial did not show any survival benefit with neoadjuvant chemotherapy, which is largely consistent with results from previous trials.


J Gittens

Correspondence to: J Gittens, ST2, QE II Hospital, Welwyn Garden City, Herts, UK; jgonson72@fsmail.net
Neoadjuvant chemotherapy in operable non-small cell lung cancer

J Gittens

*Thorax* 2008 63: 20

Updated information and services can be found at:
[http://thorax.bmj.com/content/63/1/20](http://thorax.bmj.com/content/63/1/20)

*These include:*

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)